Diabetic nephropathy (DN) is a major cause of end-stage renal disease in the general population. It estimated that DN will eventually develop about 40% all patients with diabetes; therefore, prevention critical for delaying development and progression diabetic kidney disease. Despite extensive efforts, medical advances are still not successful enough to prevent In present study, we focused on c...

Diabetic nephropathy (DN) is a major cause of end-stage renal disease (ESRD) worldwide. Glycemic and blood pressure (BP) control are important but not sufficient to attenuate the incidence and progression of DN. Sodium-glucose cotransporter (SGLT) 2 inhibitors are a new class of glucose-lowering agent suggested to exert renoprotective effects in glucose lowering-dependent and independent fashio...

Clinically, the efficacy of a low-protein diet (LPD) on diabetic nephropathy is controversial. Our study clearly showed that a very-low-protein diet (VLPD) intervention improved advanced diabetic nephropathy, particularly tubulo-interstitial injuries by restoring autophagy through the suppression of the mammalian target of rapamycin complex 1 (mTORC1) pathway, in a rat model of type 2 diabetes ...

Although there have been major advances in the understanding of the molecular mechanisms that contribute to the development of diabetic nephropathy, current best practice still leaves a significant treatment gap. The incidence of diabetes and associated nephropathy is increasing, with the main cause of mortality being related to cardiovascular causes. Novel therapies which are both 'cardio-rena...

Erythropoietin (EPO) exerts (renal) tissue protective effects. Since it is unclear whether this is a direct effect of EPO on the kidney or not, we investigated whether EPO is able to protect human renal tubular epithelial cells (hTECs) from oxidative stress and if so which pathways are involved. EPO (epoetin delta) could protect hTECs against oxidative stress by a dose-dependent inhibition of r...